利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

357 条记录 (耗时 0.022 秒)

    METHOD FOR GENERATING A MULTIPLE-GENE ASSEMBLY IN A SINGLE DNA CONSTRUCT
    75.
    发明公开
    METHOD FOR GENERATING A MULTIPLE-GENE ASSEMBLY IN A SINGLE DNA CONSTRUCT 审中-公开
    在单个DNA构建体中产生多基因组装的方法

    公开(公告)号：EP3293262A1

    公开(公告)日：2018-03-14

    申请号：EP16188155.2

    申请日：2016-09-09

    申请人： Universität Potsdam

    发明人： MESSERSCHMIDT, Katrin ,  MACHENS, Fabian ,  HOCHREIN, Lena ,  MÜLLER-RÖBER, Bernd

    IPC分类号： C12N15/10 ,  C12N15/65 ,  C12N15/66

    CPC分类号： C12N15/1093 ,  C12N15/1027 ,  C12N15/1031 ,  C12N15/65 ,  C12N15/66

    摘要： Described is a method for generating a multiple-gene assembly in a single DNA construct, a kit and a single DNA construct generated by the method.
    Different assembly methods are known in the state of the art but user has to decide between scar free, sequence independent methods, which require the time consuming individual design of every assembly and modular approaches, which generate scar sequences and require laborious parts domestication.
    In order to overcome these drawbacks a method for generating a multiple-gene assembly in a single DNA construct is provided that contains freely designed scar-free level 0 assembly units in a predefined order, determined by flanking homology regions and which is sequence-independent.

    摘要翻译： 描述了用于在单个DNA构建体，试剂盒和通过该方法产生的单个DNA构建体中产生多基因组装体的方法。 现有技术中已知不同的组装方法，但用户必须在无疤痕，不依赖序列的方法之间做出决定，这些方法需要每个组件的耗时的单独设计和模块化方法，这会产生瘢痕序列并且需要费力的部件驯化。 为了克服这些缺点，提供了用于在单个DNA构建体中产生多基因组装体的方法，其包含以预定顺序自由设计的无疤痕0级组装单元，其由侧翼同源性区域确定并且是序列无关的。

    CELL MODIFICATION METHOD USING ESSENTIAL GENES AS MARKERS AND OPTIONALLY RECYCLING THESE
    76.
    发明授权
    CELL MODIFICATION METHOD USING ESSENTIAL GENES AS MARKERS AND OPTIONALLY RECYCLING THESE 有权
    使用基因基因作为标记的细胞修饰方法和可选方法回收这些方法

    公开(公告)号：EP2898076B1

    公开(公告)日：2018-03-07

    申请号：EP13763111.5

    申请日：2013-09-19

    申请人： DSM IP Assets B.V.

    发明人： LANGE, DE, Ilse ,  MEIJRINK, Bernard ,  ROUBOS, Johannes, Andries ,  OOI, Siew-loon

    IPC分类号： C12N15/65 ,  C12N15/80

    CPC分类号： C12N15/65 ,  C12N15/80 ,  C12N15/81

    摘要： The invention relates to a method for modification of a host cell at a target locus, which method comprises: providing a host cell comprising, at a first locus, at least two site-specific recombination sites and a nucleic acid having an essential function or encoding a product having an essential function; introducing into the host cell, at the target locus, a further nucleic acid having the essential function or encoding for a product having the essential function; and carrying out recombination at the first locus via the at least two site-specific recombination sites, so that the nucleic acid having an essential function or encoding a product having an essential function is rendered non-functional, thereby to modify the host cell at the target locus. The invention also relates to a cell obtainable by a method of the invention.

    THE PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION
    77.
    发明公开
    THE PURO-DHFR QUADRIFUNCTIONAL MARKER AND ITS USE IN PROTEIN PRODUCTION 审中-公开
    PURO-DHFR四分体标记及其在蛋白质生产中的应用

    公开(公告)号：EP3219733A1

    公开(公告)日：2017-09-20

    申请号：EP17169236.1

    申请日：2008-06-06

    申请人： Merck Serono S.A.

    发明人： KOBR, Michel ,  DUPRAZ, Philippe

    IPC分类号： C07K19/00 ,  C12N15/65 ,  G01N33/50 ,  C12N5/10

    CPC分类号： C12N9/96 ,  C12N2510/02 ,  C12Y105/01003 ,  C12Y203/01005 ,  G01N33/74 ,  G01N2333/90666

    摘要： This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).

    摘要翻译： 本发明涉及蛋白质的工业生产。 更具体地说，本发明涉及res-DHFR替代标记，其对应于DHFR与赋予对毒性化合物的抗性或赋予代谢优势的蛋白之间的融合。 本发明还涉及res-DHFR用于筛选目的蛋白高表达的细胞的用途。 本发明通过Puro-DHFR替代标志来说明，其对应于嘌呤霉素N-乙酰转移酶和二氢叶酸还原酶（DHFR）之间的融合。